Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as hepatic steatosis (>5% liver triglyceride content) in the absence of significant alcohol consumption (<20g/day women, <30g/day men). It represents the hepatic manifestation of metabolic syndrome, driven by insulin resistance, chronic inflammation, and dysbiosis. NAFLD exists on a spectrum from simple steatosis to NASH (non-alcoholic steatohepatitis with hepatocyte injury), Fibrosis, cirrhosis, and hepatocellular carcinoma.
Think of your liver as a factory warehouse with three critical functions: (1) receiving and processing incoming raw materials (fatty acids from blood), (2) manufacturing new products (triglycerides via de novo lipogenesis), and (3) shipping finished goods out (VLDL export). In NAFLD, the warehouse becomes gridlocked: the receiving dock is flooded with excess deliveries from adipose tissue (due to insulin-driven Lipolysis), the manufacturing lines run overtime producing new fat (Insulin activates SREBP-1c and ChREBP, ramping up triglyceride synthesis), but the shipping department is broken (impaired VLDL assembly and export). Fat accumulates in barrels stacked everywhere. Now the "second hit": the stagnant fat barrels start leaking toxic byproducts (Oxidative Stress, lipid peroxides), attracting an angry cleanup crew (inflammatory cytokines, activated Inflammasome), and the warehouse itself begins to deteriorate (mitochondrial dysfunction, Endoplasmic Reticulum Stress). Meanwhile, the basement plumbing is backed up—gut dysbiosis and intestinal permeability allow sewage (bacterial Endotoxaemia) to flow directly into the warehouse via the portal vein, further inflaming the scene. The warehouse loses its ability to switch to alternative energy production (hepatic ketogenesis via HMGCS2 is downregulated), meaning it's stuck burning only sugar, never fat—a sign the facility has lost Metabolic flexibility.
NAFLD develops through interconnected metabolic, inflammatory, and microbial pathways:
Phase 1 — Fat Accumulation ("First Hit"):
- Increased hepatic fatty acid uptake: insulin resistance in adipose tissue → excessive Lipolysis → elevated circulating free fatty acids → increased hepatic uptake via CD36 and fatty acid transport proteins
- De novo lipogenesis: Hyperinsulinaemia → activation of SREBP-1c (sterol regulatory element-binding protein 1c) → upregulation of lipogenic enzymes (ACC, FAS, SCD-1); excess dietary fructose → activation of ChREBP (carbohydrate response element-binding protein) → independent lipogenic pathway; both pathways convert glucose/fructose → acetyl-CoA → malonyl-CoA → palmitate → triglycerides
- Impaired fatty acid oxidation: Insulin resistance → reduced PPARα activity → decreased expression of CPT1A, LCAD, and other β-oxidation enzymes → accumulation of fatty acids
- Reduced VLDL export: ER stress, insulin signaling defects, and apoB synthesis impairment → reduced packaging and secretion of triglycerides as VLDL particles
Phase 2 — Lipotoxicity and Inflammation ("Second Hit"):
- Oxidative stress: Accumulated lipids undergo peroxidation → formation of reactive aldehydes (4-HNE, MDA) → mitochondrial dysfunction → electron transport chain uncoupling → increased ROS production → further lipid damage (vicious cycle)
- ER stress: Lipid overload → unfolded protein response activation → PERK/IRE1/ATF6 pathways → Endoplasmic Reticulum Stress → JNK activation → insulin receptor substrate phosphorylation (serine instead of tyrosine) → worsened insulin resistance
- Inflammasome activation: Lipotoxic stress + mitochondrial ROS + free cholesterol crystals → NLRP3 inflammasome activation → caspase-1 cleavage → IL-1β and IL-18 maturation → hepatocyte pyroptosis and inflammation
- Gut-liver axis dysfunction: gut dysbiosis (decreased Akkermansia-muciniphila, Faecalibacterium prausnitzii; increased Enterobacteriaceae) + intestinal permeability (reduced ZO-1, occludin) → bacterial LPS translocation → portal circulation → hepatic TLR4 activation on Kupffer cells and hepatic stellate cells → TNF-α, IL-6, IL-1β secretion → amplification of inflammation
- Metabolic inflexibility: Chronic hyperinsulinaemia → transcriptional suppression of HMGCS2 (mitochondrial HMG-CoA synthase) → impaired hepatic ketogenesis → reduced β-hydroxybutyrate production → loss of ability to switch from glucose to fat oxidation → metabolic rigidity
Phase 3 — Fibrosis Progression:
- Chronic inflammation + lipotoxic hepatocyte death → hepatic stellate cells activation → TGF-β signaling → myofibroblast transformation → collagen I and III deposition → progressive Fibrosis → eventual cirrhosis
graph TD
A["Chronic Energy Excess + Insulin Resistance"] --> B[Increased Hepatic Fat Accumulation]
A --> C[Adipose Tissue Lipolysis]
C --> D["↑ Free Fatty Acids to Liver"]
D --> B
A --> E[Hyperinsulinaemia]
E --> F[SREBP-1c & ChREBP Activation]
F --> G["De Novo Lipogenesis ↑"]
G --> B
E --> H["PPARα Suppression"]
H --> I["β-Oxidation ↓"]
I --> B
B --> J[Lipotoxicity]
J --> K[Mitochondrial Dysfunction]
K --> L["ROS Production ↑"]
L --> M[Lipid Peroxidation]
M --> J
J --> N[ER Stress]
N --> O[UPR Activation]
O --> P[JNK Pathway]
P --> Q[Worsened Insulin Resistance]
J --> R[NLRP3 Inflammasome Activation]
R --> S["IL-1β, IL-18 Release"]
T["Gut Dysbiosis + Intestinal Permeability"] --> U[Portal Endotoxaemia LPS]
U --> V[Hepatic TLR4 Activation]
V --> W[Kupffer Cell & Stellate Cell Activation]
W --> X["TNF-α, IL-6 Release"]
X --> Y[Hepatic Inflammation]
S --> Y
E --> Z[HMGCS2 Suppression]
Z --> AA[Impaired Ketogenesis]
AA --> AB[Metabolic Inflexibility]
Y --> AC[Hepatocyte Death]
AC --> AD[Stellate Cell Activation]
AD --> AE["TGF-β Signaling"]
AE --> AF[Fibrosis]
AF --> AG["NASH → Cirrhosis → HCC"]
NAFLD is the most common liver disease globally (25-30% prevalence), making it a critical intervention target in cPNI practice. It represents failed metabolic adaptation—the liver's inability to cope with chronic energy excess, hyperinsulinaemia, and inflammatory burden, a quintessential mismatch disease between modern dietary patterns (high fructose, refined carbohydrates, ultra-processed foods) and ancient metabolic machinery designed for intermittent nutrient availability.
cPNI Integration:
- Selfish Brain: The liver becomes insulin-resistant to preserve glucose for cerebral metabolism, but this "selfishness" backfires as hepatic steatosis impairs overall metabolic coordination
- selfish immune system: Chronic low-grade hepatic inflammation recruits immune resources, diverting them from pathogen surveillance and tissue repair
- gut-liver axis: NAFLD demonstrates bidirectional gut-liver crosstalk—dysbiosis drives hepatic inflammation via portal Endotoxaemia, while impaired bile acid metabolism (due to hepatic dysfunction) further disrupts microbial composition
- Evolutionary mismatch: Modern humans consume 10-20x more fructose than ancestral hunter-gatherers, overwhelming the liver's fructolytic capacity and driving uncontrolled de novo lipogenesis
Clinical Markers:
- Steatosis threshold: >5% liver fat (via ultrasound, MRI-PDFF, or FibroScan CAP score >248 dB/m)
- ALT/AST elevation: Often modest (ALT 40-150 U/L); AST:ALT ratio <1 in NAFLD, >1 suggests advanced Fibrosis
- Ferritin: Often elevated (>200-300 ng/mL) reflecting iron-driven Oxidative Stress and inflammation
- insulin resistance markers: HOMA-IR >2.5, fasting insulin >15 mU/L, HbA1c 5.7-6.4%
- Lipid panel: Low HDL (<40 mg/dL men, <50 mg/dL women), elevated triglycerides (>150 mg/dL), small dense LDL
- β-hydroxybutyrate: Low fasting levels (<0.2 mmol/L) indicate impaired hepatic ketogenesis and Metabolic flexibility
- Fibrosis scores: FIB-4 index >1.3, NAFLD Fibrosis Score, elastography (>7 kPa suggests significant fibrosis)
Intervention Approach:
- Restore insulin sensitivity: Time-restricted eating (16:8 minimum), ketogenic diet or low-carb (<100g/day), resistance training (activates Akt pathway, GLUT4 translocation in muscle)
- Reduce hepatic lipogenesis: Eliminate fructose (no fruit juice, minimize added sugars), Omega-3 supplementation (EPA 2-4g/day suppresses SREBP-1c), berberine 500mg TID (activates AMPK)
- Enhance fat oxidation: Intermittent fasting (stimulates PPARα, PGC-1α), cold exposure (activates AMPK, SIRT3), L-carnitine 2g/day (facilitates mitochondrial fatty acid transport)
- Support ketogenic capacity: Ensure adequate B-vitamins (cofactors for HMGCS2), Magnesium 400-600mg/day, avoid chronic carbohydrate overfeeding
- Heal gut barrier: Remove gluten, dairy, high-FODMAP foods if sensitive; L-glutamine 5g BID, zinc carnosine 75mg BID, Collagen peptides 10-20g/day
- Modulate microbiome: Akkermansia-muciniphila supplementation or stimulation via polyphenols (e.g., resveratrol, quercetin), prebiotic fiber (inulin, resistant starch), probiotic strains (Lactobacillus rhamnosus GG, Bifidobacterium infantis)
- Reduce systemic inflammation: Targeted anti-inflammatory nutrition (Curcumin 1g/day, EPA/DHA 2-4g/day, ginger, resveratrol), stress management (chronic stress → cortisol resistance → hepatic inflammation)
- Address portal endotoxemia: Reduce alcohol completely, optimize oral health (periodontal disease → systemic LPS), consider intermittent berberine or neem as LPS scavengers
Reversibility: Early-stage NAFLD (simple steatosis without fibrosis) is fully reversible with 5-10% body weight loss and metabolic interventions. Even NASH with mild-moderate fibrosis can regress. Advanced fibrosis (F3-F4) is more challenging but stabilization is achievable. This makes NAFLD a high-leverage intervention point—catching it early prevents progression to cirrhosis and hepatocellular carcinoma.
- Affects 25-30% of global population; rising to 50-70% in individuals with Type 2 Diabetes or obesity
- Defined as >5% hepatic steatosis without significant alcohol consumption (<20-30g/day)
- Strongly associated with metabolic syndrome: 90% of NAFLD patients have ≥1 metabolic syndrome component
- Progression rates: 20-30% of NAFLD → NASH, 10-15% of NASH → cirrhosis over 5-10 years
- hepatocellular carcinoma risk increased even in non-cirrhotic NAFLD (1% per year in NASH with advanced fibrosis)
- Fructose is 7-10x more lipogenic than glucose per gram in the liver
- HMGCS2 downregulation (>50% reduction) occurs early in NAFLD, indicating impaired Metabolic flexibility
- gut dysbiosis signature: decreased Akkermansia-muciniphila and Faecalibacterium prausnitzii, increased Escherichia coli and Enterobacteriaceae
- Portal Endotoxaemia: LPS levels 2-3x higher in NAFLD patients vs. controls, correlating with disease severity
- intestinal permeability: increased zonulin (>40 ng/mL) and LPS-binding protein (>15 μg/mL) in NAFLD
- Mitochondrial dysfunction markers: reduced cytochrome c oxidase activity, decreased ATP production (20-30% reduction), increased mtDNA damage
- Inflammasome activation: NLRP3 and ASC protein levels elevated 2-4x in NAFLD liver biopsies
- Weight loss threshold for improvement: 5% body weight loss improves steatosis, 7-10% needed to improve NASH inflammation and fibrosis
- PPARα agonists (fibrates) and AMPK activators (metformin, berberine) show clinical benefit in trials
- Dietary Omega-3 index <4% correlates with NAFLD severity; target >8% for therapeutic effect
- NASH — progressive form of NAFLD with hepatocyte inflammation, ballooning, and cell death; mediated by NLRP3 inflammasome and Oxidative Stress
- insulin resistance — primary driver via dual mechanism: drives de novo lipogenesis through SREBP-1c activation and impairs hepatic fat oxidation via PPARα suppression
- de novo lipogenesis — hyperinsulinaemia + excess carbohydrates (especially fructose) activate SREBP-1c and ChREBP → increased triglyceride synthesis
- hepatic ketogenesis — impaired in NAFLD due to HMGCS2 downregulation; low fasting β-hydroxybutyrate (<0.2 mmol/L) indicates lost Metabolic flexibility
- HMGCS2 — rate-limiting enzyme for ketone body synthesis; transcriptionally suppressed by chronic hyperinsulinaemia in NAFLD
- gut dysbiosis — reduced beneficial taxa (Akkermansia-muciniphila, Faecalibacterium prausnitzii) and increased pathobionts contribute to portal Endotoxaemia
- intestinal permeability — "leaky gut" allows bacterial LPS to reach liver via portal circulation, activating TLR4 on Kupffer cells and hepatic stellate cells
- Endotoxaemia — portal LPS translocation drives hepatic inflammation; plasma LPS 2-3x higher in NAFLD, correlating with NASH severity
- metabolic syndrome — NAFLD is hepatic manifestation; shares underlying pathophysiology of insulin resistance, visceral adiposity, dyslipidemia, and chronic inflammation
- mitochondrial dysfunction — impaired oxidative capacity contributes to lipid accumulation and ROS production; reduced SIRT3 and PGC-1α activity
- Endoplasmic Reticulum Stress — lipid overload triggers UPR; PERK/IRE1/ATF6 pathways activated, leading to JNK signaling and worsened insulin resistance
- Inflammasome — NLRP3 inflammasome activation by lipotoxic stress, mitochondrial ROS, and cholesterol crystals drives IL-1β release and hepatocyte pyroptosis
- PPARα — master regulator of fatty acid oxidation; suppressed in NAFLD leading to reduced Beta-oxidation and fat accumulation
- AMPK — energy sensor downregulated in NAFLD; its activation (via metformin, berberine, exercise) improves insulin sensitivity and lipid oxidation
- Fibrosis — chronic inflammation and lipotoxic hepatocyte death activate hepatic stellate cells → collagen deposition; progression to cirrhosis in 10-15% of NASH
- Type 2 Diabetes — bidirectional relationship: insulin resistance drives NAFLD, while hepatic steatosis impairs glucose homeostasis (reduced hepatic insulin sensitivity)
- Oxidative Stress — lipid peroxidation generates reactive aldehydes (4-HNE, MDA) that damage mitochondria and activate inflammatory pathways
- inflammatory cytokines — TNF-α, IL-6, IL-1β released by Kupffer cells and infiltrating immune cells perpetuate hepatic inflammation and insulin resistance
- adipose tissue — insulin-resistant adipocytes undergo excessive Lipolysis, flooding liver with free fatty acids; also secrete pro-inflammatory adipokines (leptin, resistin)
- TLR4 — pattern recognition receptor on hepatic immune cells activated by portal LPS, triggering NF-κB signaling and inflammatory cytokine production
- hepatocellular carcinoma — NAFLD-related HCC can occur even without cirrhosis; chronic inflammation, Oxidative Stress, and DNA damage drive oncogenesis
- β-hydroxybutyrate — primary ketone body; low fasting levels in NAFLD reflect impaired hepatic ketogenesis and metabolic rigidity
- fructose — uniquely lipogenic sugar; bypasses phosphofructokinase regulation, undergoes uncontrolled hepatic metabolism → acetyl-CoA → triglycerides
- Akkermansia-muciniphila — beneficial gut bacterium reduced in NAFLD; produces Butyrate and improves gut barrier function; supplementation shows promise in trials